Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

Rhea-AI Summary

On March 2, 2023, Anixa Biosciences (NASDAQ: ANIX) announced that its CEO, Dr. Amit Kumar, will present a corporate update at the company’s 2023 Annual Meeting of Stockholders on March 9 at 10:00 AM PST. The meeting will be virtual and accessible to shareholders and other interested parties via this link. Anixa focuses on developing treatments for cancer and infectious diseases, with collaborations involving cutting-edge technologies in cancer immunotherapy and COVID-19 therapeutics. The company emphasizes its unique business model of partnering with renowned research institutions.

Positive

• Collaboration with Moffitt Cancer Center for innovative CAR-T therapies.
• Development of a COVID-19 therapeutic targeting the Mpro enzyme with MolGenie GmbH.
• Novel vaccines in collaboration with Cleveland Clinic for breast and ovarian cancer.

Negative

• None.

SAN JOSE, Calif., March 2, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its CEO, Dr. Amit Kumar, will provide a corporate presentation on the company, its business model, and updates on each of its programs and will host a question and answer period after Anixa's 2023 Annual Meeting of Stockholders, being held at 10:00AM PST on March 9, 2023 in a virtual format.

Shareholders and all other interested parties may attend the meeting by going to www.virtualshareholdermeeting.com/ANIX2023. 

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company with programs addressing cancer and infectious disease.  Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the M^pro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants.  The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.  To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-provide-corporate-update-at-its-2023-annual-meeting-of-stockholders-301760537.html

SOURCE Anixa Biosciences, Inc.

FAQ

When is Anixa Biosciences' Annual Meeting of Stockholders?

The Annual Meeting of Stockholders is on March 9, 2023, at 10:00 AM PST.

Who will present at the Anixa Biosciences stockholders' meeting?

CEO Dr. Amit Kumar will provide a corporate presentation.

How can I attend Anixa Biosciences' Annual Meeting?

You can attend the meeting virtually at www.virtualshareholdermeeting.com/ANIX2023.

What programs does Anixa Biosciences focus on?

Anixa focuses on cancer treatment and prevention, as well as infectious diseases.

What partnerships does Anixa Biosciences have?

Anixa partners with Moffitt Cancer Center and Cleveland Clinic for its clinical programs.